argenx FIRST LOOK: Highlights from R&D Day
In a 3+ hour presentation, argenx shared in-depth insights on its plans for efgar, empa and other pipeline products. The developments culminate in a new vision to reach 50k patients across 10 labelled indicators and 5 new molecules in Ph3 by 2030. Our Buy rating and €492 TP remain intact.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.